3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
34
Melanoma
13
Carcinoma, Hepatocellular
13
Neoplasm Metastasis
12
Lung Neoplasms
10
Squamous Cell Carcinoma of Head and Neck
9
Neoplasms
9
Esophageal Neoplasms
9
Colorectal Neoplasms
6
Esophageal Squamous Cell Carcinoma
5
Breast Neoplasms
5
Recurrence
4
Rectal Neoplasms
4
Brain Neoplasms
4
Uterine Cervical Neoplasms
3
Triple Negative Breast Neoplasms
3
Sarcoma
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Pancreatic Neoplasms
3
Liver Neoplasms
3
Head and Neck Neoplasms
3
Cholangiocarcinoma
3
Carcinoma, Renal Cell
3
Stomach Neoplasms
2
Small Cell Lung Carcinoma
2
Radiation Pneumonitis
2
Prostatic Neoplasms
2
Pathologic Complete Response
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Neuroblastoma
2
Interventions
Vincristine
2
Temozolomide
2
Oncolytic Virotherapy
2
repotrectinib
1
pralsetinib
1
pembrolizumab
1
pamiparib
1
interferon gamma-1b
1
cixutumumab
1
Vorinostat
1
Valproic Acid
1
Thiotepa
1
Sunitinib
1
Radiotherapy
1
Radiation
1
Peripheral Blood Stem Cell Transplantation
1
ONC206
1
Melphalan
1
Maintenance Chemotherapy
1
Lomustine
1
Interleukin-12
1
Interferon-gamma
1
Immunotherapy
1
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
Etoposide
1
Erlotinib Hydrochloride
1
Doxorubicin
1
Cyclophosphamide
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neuroectodermal Tumors
×
Immunotherapy
×
Clear all
NCT02197169
2018-07-16
TARGET-I
DNAtrix, Inc.
Phase 1
Completed
37 enrolled